1.
Clin Exp Dermatol
; 39(7): 813-5, 2014 Oct.
Artículo
en Inglés
| MEDLINE
| ID: mdl-25156341
RESUMEN
Golimumab is a fully human anti-tumour necrosis factor (TNF)-α monoclonal antibody approved for use in the treatment of active rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Psoriasis induced by treatment with anti-TNF drugs is well documented, but to our knowledge, the development of clinical features of psoriasiform exfoliative erythroderma during treatment with golimumab has not been previously described.